Tun-Yhong Wisith, Chinpaisal Chatchai, Pamonsinlapatham Perayot, Kaewkitichai Sindchai
Pharmacy Program in Biopharmaceutical Sciences, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.01725-16. Print 2017 Apr.
Tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor, after conversion to tenofovir (TFV), is mainly eliminated by glomerular filtration and active tubular secretion. The major adverse effect of tenofovir is nephrotoxicity; however, the exact mechanism remains poorly understood. In this study, the ATP-binding cassette subfamily C member 11 (ABCC11; multidrug resistance protein 8 [MRP8]) transporter, which is abundant in proximal tubular cells, was demonstrated to act as an efflux transporter of tenofovir. Real-time PCR (RT-PCR) and indirect immunofluorescence assays were used to determine MRP8 overexpression in a continuous cell line. Tenofovir accumulations were assessed by cytotoxicity, cellular transport, and vesicular uptake assays. Substrate specificity was confirmed using MK-571, an MRP-specific inhibitor, and methotrexate, which served as a known substrate. Intracellular and intravesicular concentrations of tenofovir were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The 50% cytotoxic concentration (CC) of TDF in MRP8-overexpressing cells was 4.78 times higher than that of parental cells. Transport assays also showed that the intracellular accumulation of tenofovir in MRP8-overexpressing cells was 55 times lower than that in parental cells and was partly reversed by MK-571. Similarly, an "inside-out" vesicular uptake assay, using Sf9 inverted membrane vesicles to allow measuring of accumulation of the substrates into the vesicles, demonstrated a higher intravesicular concentration of tenofovir in MRP8-overexpressing vesicles than in Sf9 insect control vesicles. These effects were effectively reversed by increasing concentrations of the specific inhibitor MK-571. In conclusion, tenofovir is a new substrate of the MRP8 transporter. An alteration in the activity of this efflux pump may increase the intracellular accumulation of tenofovir in proximal renal tubular cells.
富马酸替诺福韦二吡呋酯(TDF)是一种核苷酸逆转录酶抑制剂,转化为替诺福韦(TFV)后,主要通过肾小球滤过和肾小管主动分泌消除。替诺福韦的主要不良反应是肾毒性;然而,确切机制仍知之甚少。在本研究中,在近端肾小管细胞中大量存在的ATP结合盒亚家族C成员11(ABCC11;多药耐药蛋白8 [MRP8])转运蛋白被证明是替诺福韦的外排转运蛋白。采用实时PCR(RT-PCR)和间接免疫荧光测定法来确定MRP8在连续细胞系中的过表达情况。通过细胞毒性、细胞转运和囊泡摄取试验评估替诺福韦的蓄积情况。使用MRP特异性抑制剂MK-571和作为已知底物的甲氨蝶呤来确认底物特异性。通过液相色谱-串联质谱法(LC-MS/MS)测定替诺福韦的细胞内和囊泡内浓度。在过表达MRP8的细胞中,TDF的50%细胞毒性浓度(CC)比亲本细胞高4.78倍。转运试验还表明,过表达MRP8的细胞中替诺福韦的细胞内蓄积比亲本细胞低55倍,并且MK-571可部分逆转这种情况。同样,使用Sf9倒膜囊泡的“内翻外”囊泡摄取试验,以允许测量底物在囊泡中的蓄积情况,结果表明,过表达MRP8的囊泡中替诺福韦的囊泡内浓度高于Sf9昆虫对照囊泡。这些作用可通过增加特异性抑制剂MK-571的浓度而有效逆转。总之,替诺福韦是MRP8转运蛋白的新底物。这种外排泵活性的改变可能会增加近端肾小管细胞中替诺福韦的细胞内蓄积。